Lin H, Liu J, Hou Y, Yu Z, Hong J, Yu J, et al
These are averages from controlled trial conditions
Most patients begin with a 0.25 mg dose in week one, then progress through 0.5 mg, 1.0 mg, 1.7 mg, and up to 2.4 mg maintenance depending on tolerability and clinical response
Most patients (93%) tolerate side effects well enough to continue treatment
It is useful for weight loss through effects on GLP-1 receptor activation, insulin sensitizing affects, and anti-inflammatory effect
The results of a meta-analysis indicate that GLP-1RAs can reduce major adverse cardiovascular events (MACE) such as cardiovascular death, stroke, or myocardial infarction, as well as hospital admissions for heart failure and all-cause mortality, in patients with T2D [44]